Interestingly, treatment of a third AML primagraft sample (#3) (disease stage at time of sample acquisition: primary refractory post-induction, Supplementary Table 3) with midostaurin (up to 40 nM), alone and in combination with PRT062607 across a comparatively conservative concentration range (up to only 400 nM, a 10-fold lower concentration than was used against FLT3-ITD-positive cell lines), resulted in a higher percentage in the combination of agents as compared to either agent alone (Figure 11E). This evidence concerns the gene FLT3 and acute myeloid leukemia.